A recent study reveals that patients who discontinue new weight-loss injections like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who halt conventional diet and exercise regimens.
Findings released in a leading health publication shows that while overweight individuals frequently drop substantial amounts of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month after stopping.
"Individuals using these drugs must be cognizant of the danger of rapid rebound weight gain when the medication is stopped," stated researcher Dr. Susan Jebb.
This pace of regain means a reversion to starting weight within about 18 months.
Comparing Treatments
The research, which reviewed 37 of studies involving over 9,000 of patients, compared the outcomes of these new drugs with older methods.
Researchers emphasize that people who shed pounds through diet and exercise generally experience a more gradual creep back—perhaps 0.1 kg a month—once they finish.
Understanding the Quick Regain
Experts suggest the mode of action of the injections accounts for the accelerated regain.
The injections imitate a natural hormone called GLP-1, which controls hunger.
"Artificially providing the hormone levels far above than normal may cause the body to generate a reduced amount of its own natural GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' means appetite is no longer kept in check, making binge eating far more likely."
A Chronic Issue?
The NHS recommend the jabs for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
Professionals argue that, due to the high risk of weight regain, the treatment is often life-long.
This opinion is reinforced by pharmaceutical companies, who say that the results "emphasize the chronic nature of obesity," similar to managing diseases like high blood pressure.
Patient Testimonies
Individuals who have come off the jabs report a sudden resurgence of appetite.
"It felt as if something flipping and you're instantly starving," said a patient.
This challenge is exacerbated if users have not adopted permanent lifestyle or habit changes during treatment.
Widespread Interest
Recent estimates show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is greater among women compared to men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
In conclusion, experts stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a permanent cure and long-term success relies on integrated behavioural support.
